Distinguishing the Roles of JAK/TYK2 Inhibition in Psoriasis: MOA Video Activity

Saturday, July 30, 2022, 12:00 AM - Sunday, July 30, 2023, 11:00 PM

AMA PRA Category 1 Credits™ (0.25 hours), ABIM MOC Part 2 (0.25 hours), AMA PRA Category 1 Credits™ Designated (0.25 hours)


Psoriasis is an immune-mediated disease characterized by hyperproliferation of keratinocytes resulting in a red, itchy, scaling rash that negatively impacts quality of life for patients. In addition, systemic inflammation may manifest in psoriatic disease in the joints and spine, associated inflammatory bowel disease or uveitis, and metabolic or cardiovascular disease. Systemic treatments are available for moderate-to-severe psoriasis that target specific proinflammatory cytokines. These are associated with high levels of skin disease clearance and reduction of arthritis symptoms for patients. However, not all patients respond to, or can tolerate, current biologic agents; or disease progression can occur despite optimal therapy, fueling a need for additional novel therapies. Janus kinase (JAK) inhibitors target intracellular signaling pathways of multiple cytokines active in psoriatic disease. JAK inhibitors have demonstrated efficacy in psoriatic disease but have safety concerns associated with effects on hematopoiesis and reports that show increased risk of thrombotic and cardiovascular events and malignancy. Emerging tyrosine kinase 2 (TYK2) inhibitors offer greater specificity, and a potentially greater safety profile stemming from increased specificity and selectivity. Clinicians need to differentiate between JAK-mediated cytokines and TYK2-mediated cytokines, mechanisms of action (MOA), and potential safety effects of TYK2 versus JAK inhibitors. As data emerge, clinicians will need to consider outcomes with respect to mechanisms to inform future clinical application.

To register and take this course, please go to: https://ce.paradigmmc.com/s/catalog

There are no fees for participating in this activity.

1. Compare cytokines mediated by JAKs with those mediated by TYK2 and their roles in the pathophysiology of psoriasis
2. Distinguish between the MOA of JAK and TYK2 inhibitors and implications for the treatment of psoriasis
3. Outline the potential roles of JAK and TYK2 inhibitors in the treatment of psoriasis

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Paradigm Medical Communications, LLC .

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement
The University of Cincinnati designates this live activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

PA Continuing Education 
PAs may claim a maximum of 0.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education 
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.


Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.

Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC. 

Mitigation of Relevant Financial Relationships

The University of Cincinnati adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests) over the last 24-months. All relevant relationships have been mitigated prior to the commencement of the activity.

Information regarding the new updated ACCME Standards for Integrity and Independence in Accredited Continuing Education can be found on the ACCME website.

No faculty are available for this activity at this time.

This activity is supported by an educational grant from Bristol Myers Squibb Company.